risks of using semaglutide Semaglutide: What we know about safety and cancer risk semaglutide cardiovascular risk reduction with

GLP-1s as additive value, not SGLT2i competition KDIGOs 2024 CKD guideline reinforced a shift toward multi-mechanism CKD management, positioning GLP-1s as additive, rather than competitive, with Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i)

doi: 10.1016/j.biocel.2008.01.013 219 Rubio-RuizBSerran-AguileraLHurtado-GuerreroRConejo-GarciaA

Biomarker and Metabolic Factors That Influence Dosing Response Your response to a given semaglutide unit dose depends partly on baseline metabolic markers: fasting glucose, HbA1c, insulin resistance indices, and lipid profiles

Why Lab Work Is Not Optional on GLP-1 Therapy Before getting into the questions themselves, some context is useful